Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality -42% Improvement Relative Risk Progression -59% c19early.org/s Punzalan et al. Remdesivir for COVID-19 LATE Is late treatment with remdesivir beneficial for COVID-19? Prospective study of 400 patients in Philippines (Oct 2020 - Sep 2021) Higher progression with remdesivir (p=0.0015) Punzalan et al., Frontiers in Immunology, doi:10.3389/fimmu.2023.1123497 Favors remdesivir Favors control
Utility of laboratory and immune biomarkers in predicting disease progression and mortality among patients with moderate to severe COVID-19 disease at a Philippine tertiary hospital
Punzalan et al., Frontiers in Immunology, doi:10.3389/fimmu.2023.1123497
Punzalan et al., Utility of laboratory and immune biomarkers in predicting disease progression and mortality among patients.., Frontiers in Immunology, doi:10.3389/fimmu.2023.1123497
Feb 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Prospective study of 400 hospitalized patients in the Philippines, showing higher progression with remdesivir in unadjusted results, without statistical significance.
[Gérard, Wu, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
risk of death, 42.0% higher, RR 1.42, p = 0.12, treatment 47 of 224 (21.0%), control 26 of 176 (14.8%).
risk of progression, 58.9% higher, RR 1.59, p = 0.001, treatment 93 of 224 (41.5%), control 46 of 176 (26.1%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Punzalan et al., 28 Feb 2023, prospective, Philippines, peer-reviewed, mean age 56.0, 17 authors, study period October 2020 - September 2021.
Contact: jimbz11@gmail.com.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperRemdesivirAll
Abstract: TYPE Original Research PUBLISHED 28 February 2023 DOI 10.3389/fimmu.2023.1123497 OPEN ACCESS EDITED BY Pietro Ghezzi, University of Urbino Carlo Bo, Italy REVIEWED BY Andreu Comas-Garcia, Autonomous University of San Luis Potosı´, Mexico Andrew Weber, Northwell Health, United States Antonio Lalueza, University Hospital October 12, Spain *CORRESPONDENCE Jaime Alfonso M. Aherrera jimbz11@gmail.com SPECIALTY SECTION This article was submitted to Inflammation, a section of the journal Frontiers in Immunology RECEIVED 14 December 2022 ACCEPTED 14 February 2023 PUBLISHED 28 February 2023 CITATION Punzalan FER, Aherrera JAM, de Paz-Silava SLM, Mondragon AV, Malundo AFG, Tan JJE, Tantengco OAG, Quebral EPB, Uy MNAR, Lintao RCV, Dela Rosa JGL, Mercado MEP, Avenilla KC, Poblete JB, Albay AB Jr, David-Wang AS and Alejandria MM (2023) Utility of laboratory and immune biomarkers in predicting disease progression and mortality among patients with moderate to severe COVID-19 disease at a Philippine tertiary hospital. Front. Immunol. 14:1123497. doi: 10.3389/fimmu.2023.1123497 COPYRIGHT © 2023 Punzalan, Aherrera, de Paz-Silava, Mondragon, Malundo, Tan, Tantengco, Quebral, Uy, Lintao, Dela Rosa, Mercado, Avenilla, Poblete, Albay, David-Wang and Alejandria. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Utility of laboratory and immune biomarkers in predicting disease progression and mortality among patients with moderate to severe COVID-19 disease at a Philippine tertiary hospital Felix Eduardo R. Punzalan 1,2, Jaime Alfonso M. Aherrera 1,2*, Sheriah Laine M. de Paz-Silava 3, Alric V. Mondragon 1,2, Anna Flor G. Malundo 1,2, Joanne Jennifer E. Tan 1,2, Ourlad Alzeus G. Tantengco 4,5, Elgin Paul B. Quebral 2, Mary Nadine Alessandra R. Uy 1,2, Ryan C. V. Lintao 2, Jared Gabriel L. Dela Rosa 2, Maria Elizabeth P. Mercado 6, Krisha Camille Avenilla 2, Jonnel B. Poblete 1, Albert B. AlbayJr.1,2, Aileen S. David-Wang 1,2 and Marissa M. Alejandria 1,2,7 1 Department of Medicine, Philippine General Hospital, University of the Philippines Manila, Manila, Philippines, 2 College of Medicine, University of the Philippines Manila, Manila, Philippines, 3 College of Public Health, University of the Philippines Manila, Manila, Philippines, 4 Department of Physiology, College of Medicine, University of the Philippines Manila, Manila, Philippines, 5 Department of Biology, College of Science, De La Salle University, Manila, Philippines, 6 Department of Clinical Epidemiology, Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines, 7 Institute of Clinical Epidemiology, National Institutes of Health, University of the Philippines Manila, Manila, Philippines Purpose: This study was performed to determine the clinical biomarkers and cytokines that may be associated with disease progression and in-hospital mortality in a cohort of hospitalized patients with RT-PCR confirmed moderate to severe COVID-19 infection from October 2020 to September 2021, during the first wave of COVID-19 pandemic before the advent of vaccination. Patients and methods: Clinical..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit